Similarly, NICE (Aug 2019) had also issued guidance recommending dacomitinib, within its marketing authorisation, as an option for untreated locally advanced or metastatic EGFR mutation-positive NSCLC in adults. It is recommended only if the company provides it according to the commercial arrangement.